Lilly(Eli) & Co (LLY) stock analysis

On Oct 13, 2026, our model rated Lilly(Eli) & Co (LLY) BUY with 59% confidence at a price of $1,189.45. That means most of the technical, fundamental, money-flow and news signals point to upside.

Technical picture

The 14-day RSI is 54, close to the neutral 50 line, so momentum is balanced.

MACD is above its signal line, a sign that short-term momentum is turning up.

The price is above both its 50-day and 200-day moving averages, the classic picture of an uptrend.

Volume is only 0.6x its 20-day average; light trading makes the latest move less convincing.

Trend structure and money flow

Market structure shows a bullish break of structure (BOS): price broke a recent swing high in the direction of the trend, which usually signals trend continuation.

The most recent swing high is $1,128.50 and the swing low is $847.83; traders often treat these as resistance and support.

Price is sitting in a bearish order block, a zone where large sellers stepped in before, so upside may stall here.

Fundamentals

The PEG ratio is 1.14, which looks reasonably priced for its growth.

The company reports a profit margin of 33.5% and revenue growth of +47.7%.

In its latest quarter it earned $8.38 per share, which beat the $6.58 analysts expected, with revenue +47.7% year over year.

Wall Street's average rating is 1.6 on a 1 (strong buy) to 5 (sell) scale, roughly a "buy", with an average price target of $1,330.14.

The next earnings report is expected around Oct 29, 2026; prices often move sharply around earnings.

Trade plan from the model

The model's long / bullish plan uses an entry near $1,173.50, a target of $1,319.99 (+12.5%) and a stop-loss at $1,107.28 (-5.6%).

That is a reward-to-risk ratio of about 2.2 to 1: the potential gain is larger than the potential loss.

The plan has a time limit: reassess by Oct 28, 2026 whatever the price does.

The model's one-paragraph read

Leans BUY — composite score +0.59 (BUY). Technicals: RSI 53.61, MACD bullish, price above SMA50. Fundamentals: PEG 1.14, margin 33.5%, revenue growth 47.7%. Financial results: YoY revenue +47.7%, last EPS surprise +27.4%, next earnings 2026-10-29. Smart Money Concepts: BOS bullish (trend continuation), price retesting a bearish order block. FinGPT news read: positive. Suggested levels: entry $1173.5, target $1319.99, stop-loss $1107.28, exit by 2026-10-28 (exit before next earnings (2026-10-29) -- this signal doesn't price in that report).

Past ratings for LLY

"Move since" compares each call's price with the latest analysed price.

Recent news on LLY

• Oct 13, 2026: See Which Recent 13F Filers Hold LLY But Verus Wealth Management Exited (Nasdaq)
• Oct 13, 2026: Notable Tuesday Option Activity: LLY, WULF, CNXN (Nasdaq)
• Oct 13, 2026: What Is Eli Lilly Stock's Biggest Opportunity? (Trefis)
• Oct 13, 2026: Walmart to cover some GLP-1s, inhalers and insulin for employees at no cost as it expands benefits (CNBC)

Other Healthcare stocks we cover

MDT · NRC · NVO · OSCR · PCRX · PGNY · PHR · PRGO · SDZNY · SNN · STE · TCMD

Frequently asked questions

Is LLY a buy right now?

As of Oct 13, 2026, our automated model rates Lilly(Eli) & Co (LLY) BUY with 59% confidence: most of the technical, fundamental, money-flow and news signals point to upside. This is a model output for education, not personal investment advice.

What is the price target for LLY?

The model's most recent plan targets $1,319.99 with a stop-loss at $1,107.28, from an entry near $1,173.50.

When does Lilly(Eli) & Co report earnings next?

The next earnings report is expected around Oct 29, 2026.

What does a BUY rating mean?

A BUY rating means most of the technical, fundamental, money-flow and news signals point to upside.